This document discusses genetic testing for prostate cancer and its implications. It summarizes that genetic testing can change screening recommendations, impact treatment of advanced disease, and be life-saving for family members. It provides examples of significant family histories and genetic syndromes that increase prostate cancer risk. Major findings are that 11.8% of men with metastatic prostate cancer had germline DNA repair gene mutations, and that BRCA2 and BRCA1 carriers have higher risks of positive biopsy and poorer prognosis prostate cancer. The document concludes that genetic testing is indicated for those meeting risk criteria to help guide screening and treatment.